All In Biotech

Drug Trial Radar · NCT07704697

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

Efficacy and Safety of Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan: A Phase III, Multicenter, Randomized, Double-blind, Parallel-controlled, 12-week Clinical Study

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 346 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

346

Actual

Start

Nov 23, 2024

Primary completion

Nov 10, 2025

Study completion Nov 24, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).

Conditions

  • Essential Hypertension

Interventions

  • Experimental: Sacubitril/Allisartan and Amlodipine GroupDrug

    Drug: Sacubitril/Allisartan and Amlodipine

  • Active Comparator: Sacubitril/Allisartan GroupDrug

    Drug: Sacubitril/Allisartan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The baseline change in mean seated systolic blood pressure (msSBP)Time frame: at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.